Aortech Share Discussion Threads

[turbotrader2] 11/1/2019 14:50

Boredom Is setting in here!Very very frustrating

[bones] 10/1/2019 07:57

Thank you Sir!

[cocker] 09/1/2019 21:48

You might just make DS at this rate Bones.

[bones] 09/1/2019 20:45

One more passing observation:

Taken from fund-raising circular in May 2018:

"FUNDRAISING STATISTICS
Closing Price per Existing Ordinary Share on 18 May 2018 = 44 pence" (before issue of new shares at 30p)

Closing price today (9th Jan 19) = 45 pence

I do believe the market is not giving AOR much credit!

[bones] 09/1/2019 20:28

While looking about at Companies House, I also looked up RUA Medical, AOR's partner on the grafts and patches strategy.

This is a perfectly normal company, with straightforward shareholder structure and regular profits. The point of interest, as disclosed at the time of the fund raising in June 18, is that its sole director and owner, David Richmond, is also now a non-executive director at AOR.

Purely speculative hat on here, but I can see how it might be commercially attractive at a future date to acquire or merge the two companies. RUA looks, on the figures, to be a very decent business, right in AOR's line of business.

Anyway, food for thought! Could be way out and DYOR as always....

[bones] 09/1/2019 20:19

To pass the time, I've been doing a bit of digging in Companies House on a few companies of interest to me (not just AOR).

I found an intriguing development on AOR, albeit purely administrative:

As of last week, the Company Secretary role (which is a legally important appointed officer role that requires disclosure at Companies House) changed at Aortech International plc and its subsidiaries.

The new Company Secretary is now a lady called Kathryn Full. She has one other Company Secretary role disclosed at Companies House and that is and remains Co Sec (since 2010) for Vascular Flow Technologies Ltd ("VFT"), the company that AOR has appointed to do all of its work on the heart valve development following the fund raising in June 18.

The previous Co Secretary was based at the AOR Surrey HQ which makes me speculate that they might close those offices (?) seeing as they seem to have no geographical purpose now that all the action is in Scotland (and the USA where John Ely, the non-exec director and heart valve expert for AOR resides, as does Biomerics LLC, AOR's contract polymer manufacturer).

VFT is essentially an R&D company these days. It makes very little turnover yet, over the years, has burned through £20M if I read the accounts correctly, some of it financed from offshore investors. There was a $10m financing round in 2016 which cleared out some previous investor loans. Clearly though, the cutting edge work they are doing on blood flow computer simulation (from which AOR hope to benefit) has massive potential.

VFT's private shareholder structure seems convoluted, not surprising I guess. The investors there must be impressed as they keep topping up to finance the progress.

Anyway, my interest has been piqued by this change of Co Sec at AOR. It seems to be somehow significant that they have taken on the person from their R&D partner, VFT which is independent in all other respects, with its own customers.

Perhaps the thinking was simply the need to have someone based in Scotland and that this person came highly recommended. Perhaps it was a requirement of Scottish Enterprise to have Scottish officers and offices? Maybe there is more to the relationship going forward between AOR and VFT?

I am merely thinking and speculating aloud but think it is of interest, especially as I have a decent-sized personal interest in the quoted shares of AOR and information is not readily made available as the share price shoots all over the shop!

[turbotrader2] 08/1/2019 20:09

Bloody painful this share lol

[bones] 07/1/2019 12:20

Looks like you against the world turbo! I added around 20k before Christmas in the 40's but I am holding now as I have plenty.Seems to be a distressed seller about still. A couple of 15k disposals have occurred recently. There's bound to be plenty of people with severe margined losses from the last three months' market washout who are liquidating whatever they own.I still don't feel there has been a general market final puke yet. It's all been too orderly! In the US, Trump is trying to talk up the stock market while convincing no one that he is the next messiah while the Brexit debate is not helping the market out here.

[turbotrader2] 07/1/2019 10:44

Those last two trades are my buys had a dig around the back of my sofaLol

[semper vigilans] 07/1/2019 10:29

Time for some news I think.

[bones] 02/1/2019 08:23

Seems fair.

[bones] 31/12/2018 13:12

When something triggers interest in AOR's activities, there should be a decent move up given the near zero interest in the stock these last three months. I am happy to be well positioned for that move.Happy New Year to everyone!

[turbotrader2] 31/12/2018 11:08

Added for new year

[smcl] 19/12/2018 17:47

Yeh but I wouldn’t worry - would you listen to that dippy and take action??

[bones] 19/12/2018 17:26

Net, that's what I call a proper Xmas ramp!

[smcl] 19/12/2018 14:12

Let’s hope so but with AIM could just as easily be 14p!!

[netcurtains] 19/12/2018 14:10

This will be £14 a share by Christmas 2019 - touchwood!

[bones] 18/12/2018 18:28

So, we now know someone dumped near enough 50k yesterday morning to set the slide off then (52p was way below the bid at the time). More capitulation?

[bones] 18/12/2018 12:52

It is worth recalling what the CEO of RUA Medical (Caroline Stretton) said upon signing up with Aortech to develop patches and grafts:

"The team at RUA Medical is delighted to be partnering with AorTech on the development and supply of their transformational devices. Superior safety and performance, in conjunction with secure supply, will afford spectacular improvements to the quality of life of end users. RUA Medical also recognises the exciting future prospect of exploiting further medical device opportunities within AorTech's novel platform technology."

It is good to know they should be developing the first grafts from the in-house specialist yarns right now. Then we have the in-house specialist compliance company to usher all these products through testing and regulation. It is bound to take time but essential to get the processes right and in accordance with the latest guidelines.

[turbotrader2] 18/12/2018 12:35

Took another few